FXR expression in rats of hilar cholangiocarcinoma

Meng-yu Zhang1, Ming Luo1 & Jie-ping Wang2

The study objective was to detect the expression of farnesoid X receptor (FXR) in a rat model of hilar cholangiocarcinoma to provide a new therapeutic target for gene therapy in hilar cholangiocarcinoma. Sixty male Wistar rats (weighing 190 ± 8 g) were randomly divided into three groups (experimental group, control group and sham operation group, 20 rats in each group). The three groups were fed a standard diet. The QBC939 cell suspension of cholangiocarcinoma was injected into the hilar bile duct in the experimental group with a microsyringe. The control group was injected with normal saline, and the sham operation group was not injected with any drugs. A modified tail suspension test (TST) was used to evaluate the mental state and physical activity of rats every day. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. After one and half months, hilar cholangiocarcinoma only occurred in the experimental group. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. FXR expression in the hilar bile duct was detected by real-time polymerase chain reaction (RT–PCR) and immunohistochemistry. After two weeks, the rats in the experimental group ate less, and their weight was significantly reduced. One and half months later, hilar cholangiocarcinoma was detected in 16 rats in the experimental group. The levels of alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. The ratio of FXR/GAPDH mRNA was significantly different among the hilar cholangiocarcinoma, control and sham operation groups. Under the light microscope, FXR protein reacted with anti-FXR antibody and showed granular expression. Every pathological section included 4800 cells. A total of 1856 positive cells were in the experimental group, 3279 positive cells were in the control group, and 3371 positive cells were in the sham operation group. FXR expression in the hilar cholangiocarcinoma of rats was significantly lower than that in normal hilar bile duct tissues, suggesting that drugs targeting FXR may be a new strategy for the treatment of hilar cholangiocarcinoma.

Malignant tumours may appear in all parts of the liver and biliary system, and hilar cholangiocarcinoma is one of the malignant tumours of the biliary system. Although its incidence rate is not high, its malignancy rate is very high. According to the statistics of medical institutions at all levels, the mortality of hilar cholangiocarcinoma is high. Patients with hilar cholangiocarcinoma in the early stage have no obvious symptoms because the bile duct has not been completely blocked. With the further development of the disease, when most of the biliary tract is blocked or when it is completely blocked, jaundice, impaired liver function and acute cholangitis may occur. At this time, the disease has entered the middle and late stages, and treatment is very difficult1–3. Surgery is the preferred method, but the number of patients who can undergo surgery is very limited. According to the Bismuth Corlett classification, only type I and type II hilar cholangiocarcinomas meet the requirements of radical resection, but type III and type IV hilar cholangiocarcinomas often cannot be completely resected. Some patients can have palliative surgery, but the 5-year survival rate is low. Some patients could not get the chance of operation because of tumour invasion, metastasis, cardiopulmonary insufficiency and severe liver function damage. Alternative therapies include immunotherapy, radionuclide therapy, chemotherapy, interventional therapy, and radiofrequency ablation. However, after clinically applied, they cannot significantly improve the survival rate. Therefore, there is an urgent need for new treatments.

Gene therapy is a new method in tumour therapy developed in recent years that has been used in the treatment of liver cancer and gastric cancer and has achieved good results. The combination of gene therapy and other treatment methods improves the survival rate of patients and the quality of life. However, few target genes have been found in hilar cholangiocarcinoma, and gene therapy has not been widely used. Therefore, researchers are

1Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China. 2Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China. *email: 3529901542@qq.com
trying to identify genes related to the pathogenesis of hilar cholangiocarcinoma as therapeutic targets. Farnesoid X receptor (FXR) is related to bile acid metabolism, and its gene and protein expression plays an important role in the occurrence and development of colon cancer, breast cancer and liver cancer[4-6]. Insook et al. found that mice without the FXR gene developed hepatocellular carcinoma on the basis of liver cirrhosis. In previous experiments, we found that NTCP and FXR expression levels showed an opposite trend in the hyperlipidaemic rat model. The expression level of NTCP in the hilar cholangiocarcinoma rat model was higher than that in the normal bile duct tissue because NTCP is the target gene of FXR and the inhibitor of FXR. Thus, we studied the expression of FXR in hilar cholangiocarcinoma and whether its role in hilar cholangiocarcinoma was enhanced or decreased, and we investigated whether FXR inhibitors have an effect on its expression in tumour tissues. We hope to find a new target for the treatment of hilar cholangiocarcinoma.

Materials and methods

Statement. The study was carried out in compliance with the ARRIVE guidelines.

Rats. Sixty Wistar rats (male, 190 ± 8 g) were provided by the Animal Experimental Center of Southwest Medical University. They were randomly divided into three groups (the experimental group, the control group and the sham operation group, n = 20 each). Before the study, the rats were healthy and were not administered any drugs.

Experimental methods. The materials used include the following: Microsyringes (HAMILTON, Switzerland), pentobarbital sodium (Beijing Younikang Biotechnology Co., Ltd.), the QBC939 human cholangiocarcinoma cell line (Shanghai Tongpai Biotechnology Co., Ltd.), DME (Sigma Inc.), anti-FXR antibody (Chemicon USA), and ABI 7500 real-time PCR detection system (USA). Frozen tissue sections were prepared using a freezing microtome, liquid nitrogen, and OCT embedding agent. The main reagents were dNTPs, buffer solution, TRizol, chloroform, and real-time PCR kits (SR1100). The sense and antisense primers used to detect FXR mRNA levels were as follows: 5′-CCTCATTTGTCTCCCAGCTT A-3′ and 3′-GCCTCCTGAAAGCAGGTCT TCA-5′. The sense and antisense primers used to detect Gapdh mRNA levels were as follows: 5′-GATGTTGGGG TATGGGTCAAGA-3′ and 3′- CTAAGAGCCAGGGCAATGC-5′. The 2-ΔΔCT method was used to normalize the data. The diameter of the needle tip of the microsyringe was 40 μm and was connected to a 100 μL syringe through a rubber tube.

Establishment of the animal model was performed, and all Wistar rats were fed a standard diet. QBC939 human cholangiocarcinoma cells were cultured in DME at 37 °C and 5% saturated humidity. The cells with poor growth were filtered out, and the cells with good growth were retained. After the cells with good growth were prepared into a cell suspension with a concentration of 1 × 106 cells/mL, Wistar rats were inoculated. After disinfection, the abdomen was cut along the median line. Then, the microinjector needle was inserted into the hilar bile duct, and 100 µL of tumour cell suspension was injected. The bleeding was stopped by pressing, the abdominal layers were closed in turn, and the operation was complete. Normal saline was injected into the bile duct in the control group, and nothing was injected into the sham operation group. The mental state, diet and physical activity of the rats were evaluated daily by comprehensive behaviour scores and Basso Beattie Bresnahan assessment. At 5 weeks, one rat in the experimental group was euthanized, and the changes in the hilar bile duct were recorded. The procedure was repeated at one and half months. Pathological examination confirmed the formation of tumours, and hilar bile duct tissues were taken from the three groups. RT-PCR was used to detect the expression levels of FXR mRNA (RNA was extracted from hilar cholangiocarcinoma and normal hilar bile duct), and GAPDH expression level served as an internal control. Immunohistochemistry was used to analyse the expression levels of FXR mRNA (RNA was extracted from hilar cholangiocarcinoma and normal hilar bile duct tissues with positive cells at a rate of > 10% were considered positive, and those with positive cells at a rate of < 10% were considered negative).

Statistical analysis. Data are presented as the mean ± SD. SPSS 22.0 statistical software was used for data analysis. The t test was used to judge the differences between two groups. The χ2 test was used to evaluate immunohistochemistry data, and P<0.05 was used to indicate statistically significant differences.

Ethics approval and informed consent. The study protocol was approved by the Ethics Committee of the affiliated hospital, Southwest Medical University, Luzhou, Sichuan Province, China. Number:2020415. Animal welfare guidelines abided by China Laboratory Animal Welfare Law and Animal management regulations, Number: GB/T 35892-20181.

Consent for publish. All authors have approved the manuscript and agree with publication in Scientific Reports.

Results

After two weeks, the rats in the experimental group ate less, and their weight was significantly lower than those of the other two groups. (Tables 1, 2). Three rats in the experimental group died after 6 weeks. There were no fatalities in the other two groups. Through pathologic examination, we detected hilar cholangiocarcinoma in 16
ratios were 17 ± 1.3, 39 ± 1.6 and 38 ± 1.5, respectively. After eight
gapdh

FXR
cholangiocarcinoma are not completely clear7–10. For example, hilar cholangiocarcinoma may be caused by the
related gene expression and the regulatory mechanism of specific signal transduction pathways related to hilar
changes of hilar cholangiocarcinoma, the mechanism of tumour metastasis and invasion, the changes in tumour-
diagnostic and treatment methods have been developed in basic and clinical research, the pathophysiological

giocarcinoma include bile duct stones, primary sclerosing cholangitis and congenital cholangiectasis and that

to effectively administer. Although in the past few years, we have known that the factors related to hilar cholan-
high, especially for hilar cholangiocarcinoma, which is difficult to resect, and conventional treatment is difficult
Among the malignant tumours of the digestive system, the degree of malignancy of biliary system tumours is

Discussion

Table 1. Daily food-intake (g). ^P < 0.05 compared with the experimental group, ^P < 0.05 compared with the
experimental group, #P < 0.05 compared with the experimental group. After 2 weeks the rats in experimental group ate less, and their weight was significantly reduced compared with the other two groups.

| Week | Control group (n=20) | Sham operation group (n=20) | Experimental group (n=20) |
|------|---------------------|-----------------------------|--------------------------|
| 2    | 18.92 ± 0.05        | 19.05 ± 0.07                | 19.01 ± 0.06             |
| 3    | 23.21 ± 0.11        | 23.58 ± 0.12                | 21.85 ± 0.10             |
| 4    | 26.93 ± 0.08*       | 27.02 ± 0.09*               | 19.47 ± 0.05             |
| 5    | 28.89 ± 0.12*       | 29.10 ± 0.13*               | 18.14 ± 0.03             |

Table 2. Body mass (g). ^P < 0.05 compared with the experimental group, ^P < 0.05 compared with the
experimental group, #P < 0.05 compared with the experimental group. After 2 weeks the rats in experimental group ate less, and their weight was significantly reduced compared with the other two groups.

| Week | Control group (n=20) | Sham operation group (n=20) | Experimental group (n=20) |
|------|---------------------|-----------------------------|--------------------------|
| 2    | 206 ± 3.8           | 207 ± 4.1                   | 207 ± 4.3                |
| 3    | 220 ± 4.5           | 221 ± 4.9                   | 220 ± 4.7                |
| 4    | 237 ± 5.8*          | 238 ± 6.1*                  | 205 ± 4.2                |
| 5    | 250 ± 6.2*          | 251 ± 6.4*                  | 196 ± 3.9                |

rats (80%) in the experimental group after six weeks (Fig. 1A). The changes in liver function in the three groups
are shown in Table 3.

Analysis of FXR expression. Through RT–PCR, we found that in the hilar cholangiocarcinoma, control
and sham operation groups, the FXR/Gapdh ratios were 17 ± 1.3, 39 ± 1.6 and 38 ± 1.5, respectively. After eight
cycles, there was a significant difference among the three groups (between the experimental group and the con-
group, t = 3.217, P < 0.05; between the experimental group and the sham operation group, t = 3.185, P < 0.05) (Fig. 1B).

FXR protein reacted with the anti-FXR antibody, and FXR protein expression is shown in Fig. 1C. Every
pathological section included 4800 cells. A total of 1856 positive cells (38.7%) were in the experimental group,
3279 positive cells (68.3%) were in the control group, 3371 positive cells (70.2%) were in the sham operation
group, and there was significant difference among the three groups (χ² = 33.97, P < 0.05, between experimental
group and sham operation group; χ² = 33.16, P < 0.05, between experimental group and control group.).

Discussion

Among the malignant tumours of the digestive system, the degree of malignancy of biliary system tumours is
high, especially for hilar cholangiocarcinoma, which is difficult to resect, and conventional treatment is difficult
to effectively administer. Although in the past few years, we have known that the factors related to hilar cholan-
giocarcinoma include bile duct stones, primary sclerosing cholangitis and congenital cholangiectasis and that
diagnostic and treatment methods have been developed in basic and clinical research, the pathophysiological
changes of hilar cholangiocarcinoma, the mechanism of tumour metastasis and invasion, the changes in tumour-
related gene expression and the regulatory mechanism of specific signal transduction pathways related to hilar
cholangiocarcinoma are not completely clear7–10. For example, hilar cholangiocarcinoma may be caused by the
accumulation and interaction of specific factors, but these factors that can lead to the occurrence of tumours
and promote the progression of tumours may regulate each other, and it is uncertain how this is achieved, which
may explain the lack of effective treatment. Usually, early or smaller tumours can be completely removed, and
the prognosis is good. However, if the tumour infiltrates surrounding tissues or metastasizes, surgery is not
possible. The effects of chemotherapy, microwave ablation and radiotherapy are limited. The recurrence and
metastasis rates are high, and the 5-year survival rate is low. Therefore, there is an urgent need for more effec-
tive diagnostics and treatment methods. Gene therapy is a new method developed in recent years and has great
potential; although it has been used in the treatment of gastric cancer and liver cancer in the digestive system,
it is not widely used in the treatment of other tumours. Therefore, researchers are trying to identify genes related
to the pathogenesis of hilar cholangiocarcinoma as therapeutic targets11–13.

FXR is usually expressed on the surface of hepatocytes and bile ducts, and its function is to regulate the secre-
tion and reabsorption of bile acids. It is an important part of the enterohepatic circulation of bile acids. Bile acids
are first synthesized by hepatocytes, and bile is transported to the intestine by a bile salt export pump (BSEP).

After bile acids enter the small intestine, approximately 95% of conjugated bile acids are reabsorbed. NTCP
are first synthesized by hepatocytes, and bile is transported to the intestine by a bile salt export pump (BSEP). NTCP
mediates approximately 80% of the transport of bile acids into hepatocytes, and these bile acids are secreted into
bile again to promote the enterohepatic circulation of bile acids14–17. Because BSEP and NTCP are the target
genes of FXR, FXR plays an important role in stabilizing bile acid concentration. If the expression level of FXR
is abnormal, disorders in bile acid secretion and reabsorption may occur. When FXR levels decrease, BSEP levels
decrease synchronously, while NTCP levels increase. Therefore, bile acid secretion is insufficient, and reabsorption is excessive. The enterohepatic circulation of bile acid cannot proceed smoothly, bile will accumulate in the bile duct, and components in bile may deposit in the bile duct, leading to cell degeneration, cholangitis and stone formation. The long-term existence of cholangitis and bile duct stones is one of the possible reasons for the development of hilar cholangiocarcinoma. Therefore, a better understanding of the expression of FXR in hilar cholangiocarcinoma plays an important role in identifying new treatment methods.

Previous studies have shown that the expression level of FXR in hepatocellular carcinoma was significantly decreased, and the incidence of liver tumours in FXR gene knockout mice was 100%. FXR deletion can activate the Wnt/β-catenin and RalA-GTP carcinogenic pathways, leading to hepatocarcinogenesis. In patients with hepatitis B, FXR deletion can promote the occurrence of liver cancer by reducing the transcriptional activity of FXR-KNG1 signalling. In vitro cell experiments have demonstrated that FXR is expressed in hepatocellular carcinoma cells and that FXR agonists can inhibit the proliferation of hepatoma cells. Animal experiments have also
found that FXR expression levels are increased in liver cancer tissues and that FXR agonists can inhibit tumour growth. We previously found that NTCP was expressed in liver cancer and cholangiocarcinoma in rats and its expression levels were increased in cholangiocarcinoma. Because tumours of the liver and biliary system often affect each other, we tried to analyse whether the expression of FXR, the upstream regulatory gene of NTCP, showed a similar change in the tumours of the biliary system of rats. It is uncertain whether FXR was expressed in hilar cholangiocarcinoma, whether its levels are increased or decreased, and whether FXR agonists can play a therapeutic role. Hilar cholangiocarcinoma is often difficult to radically resect in the biliary system. Therefore, we designed this experiment to preliminarily investigate the expression of FXR in hilar cholangiocarcinoma.

In the study, six weeks after drug injection, an experimental model of hilar cholangiocarcinoma induced by QBC939 injection was successfully established in the experimental group. Due to the existence of tumours, the bile secretion of rats was blocked, and digestive function was seriously affected. Therefore, from the second week to the fifth week, the food intake of rats in the experimental group decreased, and then the body weight decreased. However, because there was no tumour effect, the opposite change was observed in the control group and sham operation group. Similarly, we found that the damage to liver function was more serious in the experimental group, and the levels of total cholesterol, total bilirubin, direct bilirubin, alanine aminotransferase and aspartate transaminase in the experimental group were higher than those in the other two groups. In other words, the bile in the experimental group had been silted after bile duct obstruction, which was an important reason for the formation of cholangitis. Simultaneously, muddy stones emerged from the bile ducts of rats in the experimental group. Through RT–PCR and immunohistochemistry, we found that the expression level of FXR in hilar cholangiocarcinoma was lower than that in the control group and sham operation group, and the differences in expression produced significant differences. Therefore, we confirmed that if the amount of bile acids in the bile duct increases, the expression of FXR level will increase and will accelerate the secretion of bile acids and reduce the reabsorption of bile acids to maintain the stability of enterohepatic circulation. However, in hilar cholangiocarcinoma, the expression level of FXR greatly decreased, and bile acid secretion significantly decreased. Therefore, cholestasis in the bile duct may occur, and the components in the bile may deposit to form stones, causing cell degeneration and inflammation around the bile duct, resulting in the phenomenon of bile duct cell destruction, proliferation and destruction alternately. The repeated destruction and proliferation of bile duct cells increase the possibility of cells with malignant phenotypes.

At present, there are very few drugs that can play a role in the treatment of hilar cholangiocarcinoma, and different problems have been found in the treatment process. For example, the scope of their use is very limited. On the one hand, only a small number of tumour tissues with clear pathological classification will respond to drugs. On the other hand, a large dose is needed, which has adverse effects on liver and kidney function and the digestive system, causing liver and kidney dysfunction and gastrointestinal bleeding, so tolerance to these drugs is poor. The drugs in the research and development stage do not directly target the genes related to hilar cholangiocarcinoma. Therefore, after FXR expression detection, we performed another experiment. In preliminary studies, we found that the FXR agonist obeticholic acid inhibits hilar CCA formation in rats (unpublished findings); however, these studies are still ongoing. GS-9674 and CS0159 have been proven to be powerful FXR agonists that can act on primary sclerosing cholangitis (PSC), and PSC has been proven to be one of the causes of hilar cholangiocarcinoma. Clinical trials for all these drugs have begun, and these agents may play a role in the treatment of hilar cholangiocarcinoma. These existing research results may enhance our understanding of the molecular basis of hilar cholangiocarcinoma and help us identify a new method for hilar cholangiocarcinoma treatment, but there are limitations at present. Although we found changes in FXR expression levels in hilar cholangiocarcinoma, and the information obtained in the current study can strengthen our understanding of the signalling pathway changes in hilar cholangiocarcinoma, the changes in genes related to FXR need to be further clarified. The effect and factors influencing the impact of drugs on FXR need to be further studied. In the next 5 years, there will be more research in this field to assess new treatments.
gene therapy has good development prospects in this field. This study may help us identify new effective therapeutic targets based on the changes in FXR.

Data availability
All data generated or analysed during this study are included in this published article.

Received: 22 December 2021; Accepted: 9 May 2022
Published online: 24 May 2022

References
1. Blehaczy, B. Cholangiocarcinoma: Current knowledge and new developments. Gut Liver 11, 13–26 (2017).
2. Anderson, B. & Doyle, M. B. M. Surgical considerations of hilar cholangiocarcinoma. Surg. Oncol. Clin. N. Am. 28, 601–617 (2019).
3. Camero, A., Sex, H. & Fara, R. Robotic left hepatectomy extended to caudate lobe and common biliary duct for hilar cholangiocarcinoma. Ann. Surg. Oncol. 29, 2407 (2022).
4. Qu, X. et al. Dysregulation of NTCP and MRP2 may play an important role in isoniazid-induced liver injury via the SIRT1/FXR pathway in rats and HepG2 cells. Biol. Pharm. Bull. 41, 1211–1218 (2018).
5. Preidis, G. A., Kim, K. H. & Moore, D. D. Nutrient-sensing nuclear receptors PPARalpha and FXR control liver energy balance. J. Clin. Invest. 127, 1193–1201 (2017).
6. Ramos Pittol, J. M. et al. FXR isoforms control different metabolic functions in liver cells via binding to specific DNA Motifs. Gastroenterology 159, 1853–1865 (2020).
7. Celotti, A. et al. Preoperative biliary drainage in hilar cholangiocarcinoma: Systematic review and meta-analysis. Eur. J. Surg. Oncol. 43, 1628–1635 (2017).
8. Wang, Y. et al. Effect of preoperative cholangitis on prognosis of patients with hilar cholangiocarcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 97, e12025 (2018).
9. Gao, F. L. et al. Insertion of I-125 seed-loaded stent for inoperable hilar cholangiocarcinoma. Wideochir Inne Tech. Maloinwazyjne 16, 678–685 (2021).
10. Lu, J. et al. Prognostic significance of mucinous component in hilar cholangiocarcinoma after curative-intent resection. J. Surg. Oncol. 120, 1341–1349 (2019).
11. Yang, X. J. et al. Application of multiple Roux-en-Y hepaticojjunostomy reconstruction by formation of bile hilar duct lake in the operation of hilar cholangiocarcinoma. World J. Clin. Cases 8, 68–75 (2020).
12. Staib, J. et al. Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: A multicenter international study. Ann. Gastroenterol. 33, 202–209 (2020).
13. Barberis, A., Rossi, U. G. & Filauro, M. Cholangitis mimicking hilar cholangiocarcinoma. Rev. Gastroenterol. Mex. 84, 245–247 (2019).
14. Zheng, B., Wang, C., Song, W., Ye, X. X. & Xiang, Z. Pharmacokinetics and enterohepatic circulation of jervine, an antitumor steroidal alkaloid from Veratrum nigrum in rats. J. Pharm. Anal. 9, 367–372 (2019).
15. Takahashi, K. & Ogra, Y. Identification of the biliary selenium metabolite and the biological significance of selenium enterohepatic circulation. Metallomics 12, 241–248 (2020).
16. Köck, K. et al. Risk factors for development of cholestatic drug-induced liver injury: Inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos. 42, 665–674 (2014).
17. Yang, F., Takeuchi, T., Tsuneyama, K., Tsuyoshi, Y. & Shingo, O. Experimental evidence of liver injury by NTCP-inhibiting drugs with a bile salt supplementation in rats. Toxicol. Sci. 170, 95–108 (2019).
18. Wang, H., He, Q., Wang, G., Xu, X. & Hao, H. FXR modulators for enterohepatic and metabolic diseases. Expert Opin. Ther. Pat. 28, 765–782 (2018).
19. Gege, C., Hambrouch, E., Hambruch, N., Kinzel, O. & Kremsoser, C. Nonsteroidal FXR ligands: Current status and clinical applications. Handb. Exp. Pharmacol. 256, 167–205 (2019).
20. Xiong, X. L. et al. Emodin rescues intrahepatic cholestasis via stimulating FXR/Ntcp pathway in promoting the canalicular export of accumulated bile. Front. Pharmacol. 10, 522 (2019).
21. Erice, O. et al. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1335–1344 (2018).
22. Di Matteo, S. et al. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma. PLoS ONE 14, e0210077 (2019).
23. Ly, B. et al. FXR acts as a metastasis suppressor in intrahepatic cholangiocarcinoma by inhibiting IL-6-induced epithelial-mesenchymal transition. Cell Physiol. Biochem. 48, 158–172 (2018).
24. Ploton, M. et al. The nuclear bile acid receptor FXR is a PKA- and FOXA2-sensitive activator of fasting hepatic gluconeogenesis. J. Hepatol. 69, 1099–1109 (2018).
25. Carino, A. et al. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis. Biochem. Biophys. Acta Mol. Cell Biol. Lipids. 185, 158733 (2020).
26. Shinohara, S. & Fujimori, K. Promotion of lipogenesis by PPARgamma-activated FXR expression in adipocytes. Biochem. Biophys. Res. Commun. 527, 49–55 (2020).
27. Jain, S., Grandits, M., Richter, L. & Ecker, G. F. Structure based classification for bile salt export pump (BSEP) inhibitors using comparative structural modeling of human NTCP. J. Comput. Aided Mol. Des. 31, 507–521 (2017).
28. Dar, F. S. et al. Outcomes after surgical resection of hilar cholangiocarcinoma. J. Coll. Phys. Surg. Pak. 29, 874–877 (2019).
29. Toumi, N. et al. Role of magnetic resonance imaging in preoperative assessment of hilar cholangiocarcinoma. Presse Med. 47, 950–960 (2018).

Author contributions
M.Z. designed the trial. M.L. did the experiment and collected the data. J.W. wrote the manuscript.

Funding
This research is supported by the project of Sichuan Science and technology department. No: 2016Y0039.

Competing interests
The authors declare no competing interests.
Additional information
Correspondence and requests for materials should be addressed to J.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022